Welcome to LookChem.com Sign In|Join Free

CAS

  • or
PIPERIDINE, 4-[(4-METHYLPHENYL)METHYL]-, HYDROCHLORIDE is a chemical compound that features a piperidine core with a 4-methylbenzyl substituent. This structure is characterized by the presence of a nitrogen atom in a six-membered ring, which is connected to a methylphenylmethyl group. The hydrochloride form indicates that it is a salt derived from the reaction of the parent compound with hydrochloric acid, which can enhance its solubility and stability in certain conditions.

165110-20-3 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 165110-20-3 Structure
  • Basic information

    1. Product Name: PIPERIDINE, 4-[(4-METHYLPHENYL)METHYL]-, HYDROCHLORIDE
    2. Synonyms: PIPERIDINE, 4-[(4-METHYLPHENYL)METHYL]-, HYDROCHLORIDE;4-(4-METHYLBENZYL)PIPERIDINE HCL;4-[(Piperidin-4-yl)methyl]toluene hydrochloride
    3. CAS NO:165110-20-3
    4. Molecular Formula: C13H19N.HCl
    5. Molecular Weight: 0
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 165110-20-3.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 298.9°C at 760 mmHg
    3. Flash Point: 137.5°C
    4. Appearance: /
    5. Density: N/A
    6. Vapor Pressure: 0.00124mmHg at 25°C
    7. Refractive Index: N/A
    8. Storage Temp.: N/A
    9. Solubility: N/A
    10. CAS DataBase Reference: PIPERIDINE, 4-[(4-METHYLPHENYL)METHYL]-, HYDROCHLORIDE(CAS DataBase Reference)
    11. NIST Chemistry Reference: PIPERIDINE, 4-[(4-METHYLPHENYL)METHYL]-, HYDROCHLORIDE(165110-20-3)
    12. EPA Substance Registry System: PIPERIDINE, 4-[(4-METHYLPHENYL)METHYL]-, HYDROCHLORIDE(165110-20-3)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 165110-20-3(Hazardous Substances Data)

165110-20-3 Usage

Uses

Used in Pharmaceutical Industry:
PIPERIDINE, 4-[(4-METHYLPHENYL)METHYL]-, HYDROCHLORIDE is used as a precursor in the synthesis of amino amide derivatives. These derivatives have potential applications as LpxC enzyme inhibitors, which are important in the development of new antibacterial agents. The LpxC enzyme is a crucial component in the biosynthesis of lipid A, a key component of the outer membrane of Gram-negative bacteria. Inhibiting this enzyme can lead to the disruption of the bacterial cell wall, making it a promising target for the treatment of bacterial infections, particularly those caused by antibiotic-resistant strains.

Check Digit Verification of cas no

The CAS Registry Mumber 165110-20-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,5,1,1 and 0 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 165110-20:
(8*1)+(7*6)+(6*5)+(5*1)+(4*1)+(3*0)+(2*2)+(1*0)=93
93 % 10 = 3
So 165110-20-3 is a valid CAS Registry Number.
InChI:InChI=1/C13H19N.ClH/c1-11-2-4-12(5-3-11)10-13-6-8-14-9-7-13;/h2-5,13-14H,6-10H2,1H3;1H

165110-20-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-[(4-methylphenyl)methyl]piperidine,hydrochloride

1.2 Other means of identification

Product number -
Other names 4-(4-METHYLBENZYL)PIPERIDINE HCL

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:165110-20-3 SDS

165110-20-3Relevant articles and documents

GLYCOSIDASE INHIBITORS

-

Page/Page column 100, (2014/10/15)

Compounds of formula (I) wherein X1, X2, W, R1 to R5, L and m have the meaning according to the claims, are glucosidase inhibitors, and can be employed, inter alia, for the treatment of Alzheimer's disease.

Controlling chemoselective transformations of 4-acylpyridines via a Pd-C catalytic hydrodechlorination-hydrogenation

Cheng, Chuanjie,Wang, Bo,Liu, Nan,Chen, Wenwen,Wang, Xinyan,Hu, Yuefei

, p. 930 - 935 (2014/01/23)

A novel Pd-C catalytic hydrodechlorination-hydrogenation was developed for a multi-step one-pot transformation of 4-acylpyridines. Under the selected conditions, 4-benzoylpyridines and 4-alkanoylpyridines were chemoselectively converted into the corresponding 4-benzylpiperidine hydrochlorides and α-alkyl-4-piperidinemethanol hydrochlorides, respectively. This catalytic method was performed simply by an addition of 1 equiv of ClCH 2CHCl2 to the conventional hydrogenation system and directly gave the crystalline piperidine hydrochlorides in practical quantitative yields.

Convenient, benign and scalable synthesis of 2- and 4-substituted benzylpiperidines

Agai, Bela,Proszenyak, Agnes,Tarkanyi, Gabor,Vida, Laszlo,Faigl, Ferenc

, p. 3623 - 3632 (2007/10/03)

A short, scalable and environmentally benign synthesis of 2- and 4-substituted benzylpiperidines has been developed. The method is based on the temperature-programmed consecutive deoxygenation and heteroaromatic ring saturation of aryl(pyridin-2-yl)- and aryl(pyridin-4-yl)methanols and aryl(pyridin-4-yl)methanones in the presence of Pd/C catalyst. The crucial roles of the temperature, the acidity and the substrate structure in the change of selectivity have been demonstrated by isolation of several substituted aryl(piperidine)methanols. The carbinols and ketones were prepared from commercially available pyridinecarbaldehydes or 4-cyanopyridine and substituted bromobenzenes via organometallic intermediates. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004.

4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists

-

, (2011/05/18)

PCT No. PCT/US96/20872 Sec. 371 Date Sep. 16, 1998 Sec. 102(e) Date Sep. 16, 1998 PCT Filed Dec. 20, 1996 PCT Pub. No. WO97/23216 PCT Pub. Date Jul. 3, 1997Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 4-substituted piperidine analogs are selective active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, psychosis, anxiety, migraine headaches, glaucoma, CMV retinitis, aminoglycoside antibiotics-induced hearing loss, convulsions, chronic pain, opioid tolerance or withdrawal, urinary incontinence or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described.

4-hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: A novel, potent, and selective NR1/2B NMDA receptor antagonist

Zhou, Zhang-Lin,Cai, Sui Xiong,Whittemore, Edward R.,Konkoy, Christopher S.,Espitia, Stephen A.,Tran, Minhtam,Rock, David M.,Coughenour, Linda L.,Hawkinson, Jon E.,Boxer, Peter A.,Bigge, Christopher F.,Wise, Lawrence D.,Weber, Eckard,Woodward, Richard M.,Keana, John F. W.

, p. 2993 - 3000 (2007/10/03)

A structure-based search and screen of our compound library identified N-(2-phenoxyethyl)4-benzylpiperidine (8) as a novel N-methyl-D-aspartate (NMDA) receptor antagonist that has high selectivity for the NR1/2B subunit combination (IC50 = 0.63 μM). We report on the optimization of this lead compound in terms of potency, side effect liability, and in vivo activity. Potency was assayed by electrical recordings in Xenopus oocytes expressing cloned rat NMDA receptors. Side effect liability was assessed by measuring affinity for α1-adrenergic receptors and inhibition of neuronal K+ channels. Central bioavailability was gauged indirectly by determining anticonvulsant activity in a mouse maximal electroshock (MES) assay. Making progressive modifications to 8, a hydroxyl substituent on the phenyl ring para to the oxyethyl tether (10a) resulted in a ~25-fold increase in NR1A/2B potency (IC50 = 0.025 μM). p-Methyl substitution on the benzyl ring (10b) produced a ~3-fold increase in MES activity (ED50 = 0.7 mg/kg iv). Introduction of a second hydroxyl group into the C-4 position on the piperidine ring (10e) resulted in a substantial decrease in affinity for α1 receptors and reduction in inhibition of K+ channels with only a modest decrease in NR1A/2B and MES potencies. Among the compounds described, 10e (4- hydroxy-N-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine, Co 101244/PD 174494) had the optimum pharmacological profile and was selected for further biological evaluation.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 165110-20-3